Komori
Revision of earnings forecasts2183Linical Co.,Ltd.Information and Communications, Services and Others

Notice Regarding Recognition of Impairment Losses (Consolidated and Non-Consolidated), Recognition of Valuation Loss on Shares of Affiliated Companies (Non-Consolidated), and the Difference between Full-Year Consolidated Earnings Forecast and Actual Results

For the fiscal year ending March 2026, consolidated actual results for net sales, operating income and ordinary income were slightly above the previous forecast, while net income attributable to owners of the parent was ¥952 million below the forecast due to impairment losses and other factors. The Company recognized consolidated impairment losses of ¥989 million and, on a non-consolidated basis, a ¥1,333 million valuation loss on shares of affiliated companies and other losses.

Worth reading
69In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
-952
million yen
Wording
Definitive
How definitive the wording is.

Revised forecast

Fiscal year ending March 2026 · Full year (1 April 2025 to 31 March 2026)Previous forecast published 18 March 2026
Net Sales8,663→8,665million yen
+0.0%
Operating profit-2,138→-2,073million yen
+3.0%
Ordinary income-2,101→-2,023million yen
+3.7%
Profit attributable to owners of the parent-2,377→-3,329million yen
-40.1%
Net income per share-105.24→-147.41yen
-40.1%

The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.

Reason for the revision

Net sales, operating income and ordinary income improved slightly due to the containment of costs and other factors, while net income attributable to owners of the parent fell below the previous forecast because impairment losses and other items were recognized as extraordinary losses.

Details and amount of extraordinary loss

Consolidated: ¥159 million in impairment losses on fixed assets in the Japan business and ¥829 million in impairment losses on goodwill in the European business, for a total of ¥989 million. Non-consolidated: ¥161 million in impairment losses on fixed assets and a ¥1,333 million valuation loss on shares of affiliated companies.

Previous-period resultsFiscal year ended March 2025: net sales ¥10,437 million; operating loss ¥583 million; ordinary loss ¥498 million; net loss attributable to owners of the parent ¥539 million; net loss per share ¥23.87
Consolidated / non-consolidatedConsolidated and standalone
Revised forecast
ItemDetails
Net Sales8,663 million yen → 8,665 million yen(0.0)
Operating profit-2,138 million yen → -2,073 million yen
Ordinary income-2,101 million yen → -2,023 million yen
Profit attributable to owners of the parent-2,377 million yen → -3,329 million yen
Net income per share-105.24 yen → -147.41 yen
Fiscal Period CoveredFiscal year ending March 2026
Period CoveredFull year (1 April 2025 to 31 March 2026)
Publication date of previous forecast18 March 2026
Previous-period resultsFiscal year ended March 2025: net sales ¥10,437 million; operating loss ¥583 million; ordinary loss ¥498 million; net loss attributable to owners of the parent ¥539 million; net loss per share ¥23.87
Reason for the revisionNet sales, operating income and ordinary income improved slightly due to the containment of costs and other factors, while net income attributable to owners of the parent fell below the previous forecast because impairment losses and other items were recognized as extraordinary losses.
Details and amount of extraordinary lossConsolidated: ¥159 million in impairment losses on fixed assets in the Japan business and ¥829 million in impairment losses on goodwill in the European business, for a total of ¥989 million. Non-consolidated: ¥161 million in impairment losses on fixed assets and a ¥1,333 million valuation loss on shares of affiliated companies.
Consolidated / non-consolidatedConsolidated and standalone
Items this document does not state (1)
Dividend forecast revision

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Net sales, operating income and ordinary income improved slightly from the previous forecast due to the containment of costs and other factors, while net income attributable to owners of the parent fell below the previous forecast because impairment losses and other items were recognized as extraordinary losses. The impairment losses were attributable to continued operating losses in the Japan and European businesses due to cancellations and delays in the launch of large-scale projects and other factors.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding Recognition of Impairment Losses (Consolidated and Non-Consolidated), Recognition of Valuation Loss on Shares of Affiliated Companies (Non-Consolidated), and the Difference between Full-Year Consolidated Earnings Forecast and Actual Results | Linical Co.,Ltd. (2183) timely disclosure | Komori